Population‐based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma

• Published in: Clinical and translational science Vol. 15; no. 12; pp. 3000 - 3011
• Main Authors: Wu, Liviawati S., Su, Yaming, Li, Claire, Zhou, Wangda, Jackson, Carolyn C., Sun, Yu‐Nien, Zhou, Honghui
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.12.2022; John Wiley and Sons Inc; Wiley
• Subjects: Adult; Antigens; Body weight; Chimeric antigen receptors; Humans; Immunotherapy, Adoptive - adverse effects; Intravenous administration; Kinetics; Lymphocytes T; Mathematical models; Multiple myeloma; Multiple Myeloma - drug therapy; Normal distribution; Pharmacokinetics; Population; Receptors, Chimeric Antigen - genetics; T-Lymphocytes
• ISSN: 1752-8054; 1752-8062; 1752-8062
• DOI: 10.1111/cts.13421

The aims of this work were to develop a population pharmacokinetic (PK) model for chimeric antigen receptor (CAR) transgene after single intravenous infusion administration of ciltacabtagene autoleucel in adult patients with relapsed or refractory multiple myeloma. CAR transgene level in blood were measured by quantitative polymerase chain reaction (qPCR) from 97 subjects in a phase Ib/II CARTITUDE‐1 study (NCT03548207), with a targeted cilta‐cel dose of 0.75 × 106 (range 0.5–1.0 × 106) CAR positive viable T‐cells per kg body weight. The population PK model development was primarily guided by the current mechanistic understanding of CAR‐T kinetics and the principles of building a parsimonious model. Cilta‐cel PK was adequately described by a two‐compartment model (with a fast and a slow apparent decline rate from each compartment, respectively) and a chain of four transit compartments with a lag time empirically representing the process from infused CAR‐T cell to measurable CAR transgene. No apparent relationship was observed between cilta‐cel dose (i.e., the actual number of CAR positive viable T‐cells infused), given the narrow dose range, and the observed transgene level. Based on covariate search and subgroup analysis of maximum systemic CAR transgene level (Cmax) and area under curve from the first dose to day 28 (AUC0–28d), none of the investigated subjects' demographics, baseline characteristics, and manufactured product characteristics had significant effects on cilta‐cel PK. The developed model is deemed robust and adequate for enabling subsequent exposure‐safety and exposure‐efficacy analyses.